TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1561524

Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg every morning for 10 days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 4015380

Group type: EXPERIMENTAL
Intervention: Combined radiation and fluorouracil as adjuvant therapy
Number of subjects: 43

Group type: COMPARATOR
Intervention: No adjuvant treatment
Number of subjects: 43
Study: 29121431

Group type: EXPERIMENTAL
Intervention: 0.05% clobetasol propionate (CP) in aqueous solution (AS)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: 0.05% triamcinolone acetonide (TA) in aqueous solution (AS)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: 0.05% clobetasol propionate (CP) in orabase (OB)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: 0.05% triamcinolone acetonide (TA) in orabase (OB)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Patients with continuous symptoms
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Patients with intermittent symptoms
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Adverse effects observed in patients
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Maintenance treatment for >6 months
Number of subjects: 102
Study: 27615399

Group type: EXPERIMENTAL
Intervention: Annual trans-vaginal ultrasound (TVU) for 4 years and CA-125 testing for 6 years with a cutoff at 35 U/mL
Number of subjects: 39105

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 39105
Study: 24219852

Group type: EXPERIMENTAL
Intervention: 4 Fr NBD catheter
Number of subjects: 165

Group type: COMPARATOR
Intervention: 6 Fr NBD catheter
Number of subjects: 165
Study: 22519736

Group type: EXPERIMENTAL
Intervention: Miglitol
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Voglibose
Number of subjects: 36

Group type: COMPARATOR
Intervention: Mix50
Number of subjects: 36
Study: 20447617

Group type: EXPERIMENTAL
Intervention: Arginine vasopressin (AVP) 20 IU
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 19083452

Group type: EXPERIMENTAL
Intervention: 1.5-g dose of strong-gelling alginate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 0
Study: 16636410

Group type: EXPERIMENTAL
Intervention: Functional Electrical Impedance Tomography (f‐EIT) based on back projection
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Simultaneous Iterative Reconstruction Technique (SIRT)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Electrical impedance tomograms
Number of subjects: 4

Group type: COMPARATOR
Intervention: Regional resistivity data
Number of subjects: 4
Study: 12941422

Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies used to deplete lymphocytes or block T-cell function
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conventional immunosuppressive agents
Number of subjects: 0
Study: 10202052

Group type: EXPERIMENTAL
Intervention: Variceal ligation
Number of subjects: 88

Group type: COMPARATOR
Intervention: Endoscopic sclerotherapy
Number of subjects: 88
Study: 7595729

Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy (PC) with cyclophosphamide 600 mg/m2, epidoxorubicin 60 mg/m2, and fluorouracil 600 mg/m2 (CEF)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy (PC)
Number of subjects: 600
Study: 2151889

Group type: EXPERIMENTAL
Intervention: Enoximone (0.5 mg/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Enoximone (0.5 mg/kg) + epinephrine (0.1 micrograms/kg/min)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Epinephrine (0.1 micrograms/kg/min)
Number of subjects: 30
Study: 161652

Group type: EXPERIMENTAL
Intervention: Björk-Shiley (B-S) valves
Number of subjects: 78

Group type: COMPARATOR
Intervention: Lillehei-Kaster (L-K) valves
Number of subjects: 78
Study: 30251569

Group type: EXPERIMENTAL
Intervention: Group prenatal care (GPC)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Individual prenatal care (IPC)
Number of subjects: 84
Study: 31577705

Group type: EXPERIMENTAL
Intervention: Early preoperative analgesia (EPA)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Postoperative analgesia (POA)
Number of subjects: 296
Study: 28370357

Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow-derived MSCs infused weekly for 4 weeks (1.0 to 10 × 10^5 cells/kg)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard medical therapy (SMT)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow-derived MSCs
Number of subjects: 110
Study: 26215351

Group type: EXPERIMENTAL
Intervention: Teething rings
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Cuddle therapy
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Rubbing the gums
Number of subjects: 270

Group type: COMPARATOR
Intervention: Ice
Number of subjects: 270

Group type: COMPARATOR
Intervention: Food for chewing
Number of subjects: 270

Group type: COMPARATOR
Intervention: Drooling
Number of subjects: 270

Group type: COMPARATOR
Intervention: Sleep disturbances
Number of subjects: 270

Group type: COMPARATOR
Intervention: Irritability
Number of subjects: 270

Group type: COMPARATOR
Intervention: Canine eruption
Number of subjects: 270

Group type: COMPARATOR
Intervention: Low grade increases in body temperature
Number of subjects: 270

Group type: COMPARATOR
Intervention: Fever
Number of subjects: 270
Study: 23692975

Group type: EXPERIMENTAL
Intervention: Listerine® oral rinse twice daily
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate oral rinse 2/24
Number of subjects: 398

Group type: COMPARATOR
Intervention: Sterile water 2/24 (control group)
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 398
Study: 21718471

Group type: EXPERIMENTAL
Intervention: 6 month intensive inpatient treatment program during weekdays, followed by six monthly return visits of 2 days (Group A)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 2 month intensive inpatient treatment program during weekdays, followed by biweekly return visits of 2 days during the next four months, followed by six monthly return visits of 2 days (Group B)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both Group A and Group B
Number of subjects: 80
Study: 19092694

Group type: EXPERIMENTAL
Intervention: Juice powder concentrate (JPC) 70%
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Juice powder concentrate (JPC) 80%
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (Plac) 70%
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (Plac) 80%
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Exercise at 80% .VO2max
Number of subjects: 41
Study: 17105987

Group type: EXPERIMENTAL
Intervention: Very obese patients (BMI >= 35 kg/m2)
Number of subjects: 4288

Group type: EXPERIMENTAL
Intervention: Underweight patients (BMI < 18.5 kg/m2)
Number of subjects: 4288
Study: 12775279

Group type: EXPERIMENTAL
Intervention: Initial surveillance followed by radical retropubic prostatectomy (mean 23.4 months, range 8‐55 months)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Immediate surgery without prior surveillance (matched control group)
Number of subjects: 26
Study: 11248828

Group type: EXPERIMENTAL
Intervention: 4% lidocaine
Number of subjects: 17

Group type: COMPARATOR
Intervention: 0.5% tetracaine
Number of subjects: 17

Group type: COMPARATOR
Intervention: 0.75% bupivacaine
Number of subjects: 17

Group type: COMPARATOR
Intervention: 0.5% tetracaine + 4% lidocaine
Number of subjects: 17

Group type: COMPARATOR
Intervention: 0.5% tetracaine + 0.75% bupivacaine
Number of subjects: 17
Study: 9892788

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily
Number of subjects: 317

Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 317
Study: 8010153

Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy (DBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dialectical techniques balancing acceptance and change
Number of subjects: 0
Study: 2643237

Group type: EXPERIMENTAL
Intervention: Valaxon tablets
Number of subjects: 12

Group type: COMPARATOR
Intervention: Valium tablets
Number of subjects: 12
Study: 23150917

Group type: EXPERIMENTAL
Intervention: Dentifrice A
Number of subjects: 43

Group type: COMPARATOR
Intervention: Dentifrice B
Number of subjects: 43
Study: 7380205

Group type: EXPERIMENTAL
Intervention: Spironolactone (200 mg/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (furosemide or paracentesis)
Number of subjects: 15
Study: 30767761

Group type: EXPERIMENTAL
Intervention: Overexpression of SiMYB3 in transgenic Arabidopsis plants
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control plants (non-transgenic Arabidopsis)
Number of subjects: 6
Study: 29446442

Group type: EXPERIMENTAL
Intervention: Self-identified vaccinated donors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-identified convalescent donors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control donors
Number of subjects: 0
Study: 27347034

Group type: EXPERIMENTAL
Intervention: Piperazine ferulate tablets combined with eucalyptol limonene pinene enteric soft capsules
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conservative or hormone therapy
Number of subjects: 60
Study: 24684853

Group type: EXPERIMENTAL
Intervention: Cold-tempered water (3 °C)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Room-tempered water (22 °C)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Body-tempered water (37 °C)
Number of subjects: 12
Study: 22413874

Group type: EXPERIMENTAL
Intervention: DRV/r monotherapy (800/100 mg once daily)
Number of subjects: 256

Group type: COMPARATOR
Intervention: DRV/r plus two NRTIs
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: DRV/r monotherapy (strict ITT analysis)
Number of subjects: 256

Group type: COMPARATOR
Intervention: DRV/r plus two NRTIs (strict ITT analysis)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: DRV/r monotherapy
Number of subjects: 256
Study: 21059484

Group type: EXPERIMENTAL
Intervention: 110 mg dabigatran
Number of subjects: 3623

Group type: EXPERIMENTAL
Intervention: 150 mg dabigatran
Number of subjects: 3623

Group type: COMPARATOR
Intervention: warfarin
Number of subjects: 3623
Study: 17995698

Group type: EXPERIMENTAL
Intervention: Low-calorie muffins (LCMs)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Plain muffins (PMs)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Bread
Number of subjects: 14
Study: 16246655

Group type: EXPERIMENTAL
Intervention: Vaginal contraceptive ring
Number of subjects: 201

Group type: COMPARATOR
Intervention: Low-dose oral contraceptive
Number of subjects: 201
Study: 12010270

Group type: EXPERIMENTAL
Intervention: Microbiological filter (Supor, Pall Life Sciences)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Control group (no filter)
Number of subjects: 336
Study: 9647138

Group type: EXPERIMENTAL
Intervention: High-dose aprotinin (30,000 KIU/kg)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin (15,000 KIU/kg)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: High-dose aprotinin with additional bolus
Number of subjects: 96
Study: 8702066

Group type: EXPERIMENTAL
Intervention: Early growth modification treatment for Class II malocclusion (duration: 15 months)
Number of subjects: 208
Study: 2198057

Group type: EXPERIMENTAL
Intervention: Plax prebrushing rinse
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 103
Study: 343994

Group type: EXPERIMENTAL
Intervention: scopolamine-N-(cyclopropyl methyl) bromide (DA 3177) at doses of 2.5 mg and 5 mg i.v.
Number of subjects: 8

Group type: COMPARATOR
Intervention: hyoscine-N-butyl bromide at doses of 10 mg and 20 mg i.v.
Number of subjects: 8
Study: 31654487

Group type: COMPARATOR
Intervention: Evobrutinib (single dose: 25, 50, 100, 200, 350, and 500 mg)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Evobrutinib (multiple dosing: 25, 75, and 200 mg/day for 14 days)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Evobrutinib (≥ 200 mg single dose)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Evobrutinib (≥ 100 mg)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Evobrutinib (25 mg multiple dosing)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Evobrutinib
Number of subjects: 84
Study: 28946799

Group type: EXPERIMENTAL
Intervention: Team-based learning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lecture
Number of subjects: 0
Study: 29105625

Group type: EXPERIMENTAL
Intervention: Jin'gangteng capsule combined with Kangfuxiaoyan suppository
Number of subjects: 97

Group type: COMPARATOR
Intervention: Kangfuxiaoyan suppository
Number of subjects: 97
Study: 26294526

Group type: EXPERIMENTAL
Intervention: New approaches based on physiological response, eye tracking, and user movement analysis
Number of subjects: 0
Study: 23413101

Group type: EXPERIMENTAL
Intervention: Omalizumab 150 to 375 mg subcutaneously every 2 or 4 weeks from week 0 to 48
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20680676

Group type: EXPERIMENTAL
Intervention: Enhanced profiles (n=74)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Basic profiles (n=29)
Number of subjects: 103
Study: 19231138

Group type: EXPERIMENTAL
Intervention: 5mg intranasal diazepam (DZP)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 10mg intranasal diazepam (DZP)
Number of subjects: 8

Group type: COMPARATOR
Intervention: 5mg intravenous diazepam (DZP injectable, 5mg/mL)
Number of subjects: 8
Study: 17268414

Group type: EXPERIMENTAL
Intervention: Herring diet (150 g baked herring fillets/day, 5 days/week)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Reference diet (pork and chicken fillets)
Number of subjects: 15
Study: 15141407

Group type: EXPERIMENTAL
Intervention: Endoscopic placement
Number of subjects: 43

Group type: COMPARATOR
Intervention: Fluoroscopic placement
Number of subjects: 43
Study: 11793034

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 128

Group type: COMPARATOR
Intervention: Neoral
Number of subjects: 128
Study: 9382049

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg a day for 1 month and amoxycillin 1 g three times daily for 14 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 16
Study: 8369641

Group type: EXPERIMENTAL
Intervention: 60 mg d,l‐fenfluramine (FEN)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 3519046

Group type: EXPERIMENTAL
Intervention: UK-38,485 (specific thromboxane synthetase inhibitor)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 31609920

Group type: EXPERIMENTAL
Intervention: Conditioned group (oxytocin nasal spray with a distinctive smell)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (placebo spray)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Drug control group (oxytocin spray)
Number of subjects: 99
Study: 30757911

Group type: EXPERIMENTAL
Intervention: Linfadren® plus conventional treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 60
Study: 28273084

Group type: EXPERIMENTAL
Intervention: Vitamin-D deficient children
Number of subjects: 960

Group type: COMPARATOR
Intervention: Vitamin-D replete children
Number of subjects: 960

Group type: EXPERIMENTAL
Intervention: Vitamin-D status (deficient vs replete)
Number of subjects: 960
Study: 25331203

Group type: EXPERIMENTAL
Intervention: TAP block with bupivacaine at a dose of 2.5 mg · kg(‐1)
Number of subjects: 36

Group type: COMPARATOR
Intervention: TAP block with bupivacaine at a dose of 1.25 mg · kg(‐1)
Number of subjects: 36
Study: 23632722

Group type: EXPERIMENTAL
Intervention: 400 IU/d vitamin D3
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: 800 IU/d vitamin D3
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: 1200 IU/d vitamin D3
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: 1600 IU/d vitamin D3
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: All dosages (400, 800, 1200, 1600 IU/d)
Number of subjects: 132
Study: 21122992

Group type: EXPERIMENTAL
Intervention: Real TMS
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham TMS
Number of subjects: 24
Study: 18268396

Group type: EXPERIMENTAL
Intervention: Interferon-alpha2a (IFN-alpha2a) administered for 6 days starting 1 week before nephrectomy.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no treatment with IFN-alpha2a).
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Interferon-alpha2a (IFN-alpha2a).
Number of subjects: 60
Study: 17133610

Group type: EXPERIMENTAL
Intervention: Low-dose prednisolone and 6 infusions (monthly) of intravenous cyclophosphamide (CYC) followed by oral azathioprine (AZA)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 14604034

Group type: EXPERIMENTAL
Intervention: Educational sessions detailing muscle physiology, neural control of muscle force, and imagery training
Number of subjects: 16

Group type: COMPARATOR
Intervention: Educational sessions about health and fitness (Control)
Number of subjects: 16
Study: 11203913

Group type: EXPERIMENTAL
Intervention: Conventional Meridol mouthrinse
Number of subjects: 80

Group type: COMPARATOR
Intervention: Alcohol-free Meridol mouthrinse
Number of subjects: 80
Study: 8857479

Group type: EXPERIMENTAL
Intervention: simvastatin 10 mg bid
Number of subjects: 22

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 22
Study: 1629507

Group type: EXPERIMENTAL
Intervention: Budesonide (600 micrograms, twice daily)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Terbutaline (375 micrograms, twice daily)
Number of subjects: 14
Study: 6860201

Group type: EXPERIMENTAL
Intervention: 0.125% betaxolol ophthalmic solution
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (drug vehicle)
Number of subjects: 20
Study: 31919749

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil plus Chinese medicine (Tiaogan Jianpi Hexue and Tiaogan Jiedu Huashi)
Number of subjects: 590

Group type: COMPARATOR
Intervention: Adefovir dipivoxil plus placebo (control group)
Number of subjects: 590
Study: 30691922

Group type: EXPERIMENTAL
Intervention: Intracameral 0.5% moxifloxacin (0.03 mL, 150 μg)
Number of subjects: 3640

Group type: COMPARATOR
Intervention: Control group (no IC medication)
Number of subjects: 3640

Group type: EXPERIMENTAL
Intervention: Intracameral 0.5% moxifloxacin
Number of subjects: 3640
Study: 28513523

Group type: COMPARATOR
Intervention: Standard triple therapy for 2 weeks
Number of subjects: 160

Group type: COMPARATOR
Intervention: Bismuth containing quadruple therapy for 2 weeks
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 5 + 5 clarithromycin‐based sequential therapy
Number of subjects: 160

Group type: COMPARATOR
Intervention: 7 + 7 clarithromycin‐based sequential therapy
Number of subjects: 160
Study: 26037777

Group type: EXPERIMENTAL
Intervention: Tocilizumab plus ongoing methotrexate
Number of subjects: 553

Group type: COMPARATOR
Intervention: Tocilizumab plus placebo
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Tocilizumab discontinuation
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: DAS28‐2 criteria
Number of subjects: 553
Study: 23522322

Group type: EXPERIMENTAL
Intervention: Lumbar fusion or cognitive intervention and exercises
Number of subjects: 93
Study: 21644315

Group type: EXPERIMENTAL
Intervention: Moxibustion pretreatment (mild moxibustion applied at Guanyuan (CV 4), Zusanli (ST 36) or Guanyuan (CV 4), Sanyinjiao (SP 6) alternatively once daily for 4 weeks)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 12
Study: 20108857

Group type: EXPERIMENTAL
Intervention: Intramuscular pressure (IMP) during isometric fatiguing extension at 60% of maximum voluntary contraction
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tissue oxygenation pressure (pO2) during isometric fatiguing extension
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Median frequency (MF) shift in the electromyographic power density spectrum during contraction
Number of subjects: 30
Study: 16454794

Group type: COMPARATOR
Intervention: Group 1 (Control): No restoration
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Group 2: Unrestored teeth
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Group 3: Restored with composite resin (AP‐X; Kuraray, Japan)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Group 4: Restored with composite resin and polyethylene woven fibre (Ribbond) placed in a groove
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Group 5: Cavity surfaces covered with flowable resin and polyethylene fibre placed into the bed of resin before composite restoration
Number of subjects: 50
Study: 15288698

Group type: EXPERIMENTAL
Intervention: L‐NMMA infusion
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Comparison of CBF between young and old subjects
Number of subjects: 15
Study: 11135717

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.10μg · kg‐1 min‐1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline-placebo
Number of subjects: 0
Study: 8290916

Group type: EXPERIMENTAL
Intervention: Chemotherapy (cisplatin 70 mg/m2 and doxorubicin 30 mg/m2, 2 cycles with 3-week interval)
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment
Number of subjects: 311

Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 311
Study: 3565525

Group type: EXPERIMENTAL
Intervention: Workbook-based occupational therapy program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional occupational therapy
Number of subjects: 0
Study: 29940980

Group type: EXPERIMENTAL
Intervention: 15-point Global Rating of Change scale (GRC)
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: five-point GRC
Number of subjects: 451

Group type: COMPARATOR
Intervention: Pulmonary Rehabilitation (PR)
Number of subjects: 451
Study: 26468947

Group type: EXPERIMENTAL
Intervention: Lapatinib at 750 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Lapatinib at 1,000 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Lapatinib at 1,250 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Lapatinib combined with Gemcitabine and Cisplatin (GC)
Number of subjects: 18
Study: 24833726

Group type: EXPERIMENTAL
Intervention: 10 cm H₂O PEEP and one recruitment manoeuvre (RM) after induction and exsufflation
Number of subjects: 50

Group type: COMPARATOR
Intervention: 10 cm H₂O PEEP (control group)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 10 cm H₂O PEEP and one RM
Number of subjects: 50